1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>Spain

Spain Bets On New Pharmaceutical Strategy To Boost Access And Innovation

 
• By Francesca Bruce

The strategy includes a committee made up of pharmaceutical industry representatives and ministers to discuss the impact of regulatory proposals.

Spain announces plans to capitalize on the pharmaceutical industry

Spain’s new three-pronged strategic plan to bolster the pharmaceutical industry will also strengthen research and innovation, improve timely access to medicines and ensure strategic autonomy in the production of medicines.

The plan will mean an overhaul of the current pricing and reimbursement system, including the creation of a new system for evaluating the efficiency of new. Improving the R&D infrastructure,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Spain

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

New Medicines Pricing Proposals Would Mean More Uncertainty For Spanish Supply Chains

 
• By Francesca Bruce

Proposals to reform Spain’s reference pricing system are out of whack with the national pharmaceutical strategy published in December, six industry associations have warned.

Spain Boosts Transparency On Reimbursement Decisions And Sheds Light On Agreements With Companies

 
• By Francesca Bruce

The first reimbursement reports published by the Spanish health ministry to improve transparency focus on CSL’s Hemgenix, BMS’ Camzyos and Pfizer’s Velsipity.

More from Legislation

Korean Pharma Industry Proposes Policies As Election Nears

 
• By Jung Won Shin

As South Korea gears up for a snap presidential election, its biopharma industry proposes key desired policies to candidates, most of whom have not laid out detailed plans of their own for the sector.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.